Get the Stockscreener App
25.16
6.26%
-1.68
After Hours:
24.96
-0.20
-0.79%
Kodiak Sciences Inc stock is traded at $25.16, with a volume of 388.45K.
It is down -6.26% in the last 24 hours and up +19.75% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$26.84
Open:
$26.51
24h Volume:
388.45K
Relative Volume:
0.49
Market Cap:
$1.54B
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-6.6915
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-10.08%
1M Performance:
+19.75%
6M Performance:
+139.16%
1Y Performance:
+548.45%
1-Day Range:
$24.96
$26.64
1-Week Range:
$24.96
$27.92
52-Week Range:
$1.92
$31.18
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
25.16 | 1.64B | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Kodiak Sciences Inc face regulatory challenges2025 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aug Retail: Is Kodiak Sciences Inc a turnaround storyJuly 2025 Setups & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Assessing Kodiak Sciences (KOD) Valuation After Baker Bros. Buying And Late Stage Retinal Trial Progress - Sahm
Kodiak Sciences (KOD) Price Target Increased by 15.58% to 36.21 - Nasdaq
Can Kodiak Sciences Inc. outperform in the next rallyPortfolio Performance Summary & Daily Stock Trend Watchlist - mfd.ru
A Look At Kodiak Sciences (KOD) Valuation After Its Strong One Year Shareholder Return - Yahoo Finance
Earnings Miss: Is Kodiak Sciences Inc stock a smart retirement pickJuly 2025 Market Mood & Fast Gain Stock Tips - baoquankhu1.vn
Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy - AOL.com
Kodiak Sciences (NASDAQ:KOD) Shares Down 5.9%Here's What Happened - MarketBeat
First Week of April 17th Options Trading For Kodiak Sciences (KOD) - Nasdaq
Will Kodiak Sciences Inc. stock remain a Wall Street favoriteJuly 2025 Market Mood & Risk Managed Investment Signals - mfd.ru
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead - AOL.com
History Review: Is Kodiak Sciences Inc a turnaround story2025 Performance Recap & Growth Focused Entry Reports - baoquankhu1.vn
Kodiak Sciences (NASDAQ:KOD) Shares Up 10.9%Should You Buy? - MarketBeat
GSA Capital Partners LLP Sells 76,735 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
Perlroth reports 9.9% Kodiak Sciences (KOD) stake in 13G/A - Stock Titan
Will Kodiak Sciences Inc. benefit from seasonality2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - mfd.ru
Will Kodiak Sciences Inc. benefit from AI trendsQuarterly Investment Review & Low Risk Growth Stock Ideas - mfd.ru
Will Kodiak Sciences Inc. outperform the market in YEAREarnings Recap Summary & Verified Entry Point Signals - mfd.ru
Will Kodiak Sciences Inc. stock outperform tech sector in 2025July 2025 Weekly Recap & AI Enhanced Market Trend Forecasts - mfd.ru
KOD Technical Analysis & Stock Price Forecast - Intellectia AI
KOD PE Ratio & Valuation, Is KOD Overvalued - Intellectia AI
Smart Money: Will Kodiak Sciences Inc benefit from AI trendsJuly 2025 Volume & Technical Pattern Alert System - baoquankhu1.vn
What are the analyst revisions for Kodiak Sciences Inc.Is BOIL stock a good investment in YEARJuly 2025 Technicals & Weekly Market Pulse Alerts - mfd.ru
H.C. Wainwright reiterates Buy rating on Kodiak Sciences stock at $38 - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Kodiak Sciences stock at $38 By Investing.com - Investing.com South Africa
KOD: HC Wainwright & Co. Reiterates Buy Rating with $38 Target | - GuruFocus
HC Wainwright Reaffirms Buy Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
Kodiak Sciences Inc. (KOD) Presents at Angiogenesis, Exudation, and Degeneration 2026Slideshow - Seeking Alpha
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - TradingView
Aug PostEarnings: Can Kodiak Sciences Inc lead its sector in growthEarnings Miss & Precise Entry and Exit Recommendations - baoquankhu1.vn
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Kodiak Sciences to present final APEX study results at Angiogenesis meeting - Investing.com Nigeria
Kodiak Sciences to present final APEX study results at Angiogenesis meeting By Investing.com - Investing.com South Africa
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 - marketscreener.com
Kodiak Sciences (KOD) Price Target Increased by 11.69% to 31.33 - Nasdaq
Kodiak Sciences raises capital through completed stock offering - MSN
Kodiak Sciences: A Stellar Move (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences: GLOW2 Readout as Key Catalyst for Tarcocimab Upside and Broader Pipeline Optionality - TipRanks
Aug Catalysts: Is Kodiak Sciences Inc exposed to currency risks2025 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn
Aug Retail: Will Kodiak Sciences Inc outperform the market in YEAR - baoquankhu1.vn
Kodiak Sciences (NASDAQ:KOD) Trading 6.5% HigherHere's Why - MarketBeat
Can Kodiak Sciences (KOD) Funding And Readouts Reshape Its Retinal Disease Treatment Narrative? - Sahm
FY2025 EPS Estimates for Kodiak Sciences Lifted by Analyst - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 7.6%Here's Why - MarketBeat
HC Wainwright Predicts Kodiak Sciences FY2030 Earnings - MarketBeat
Kodiak Sciences Reaches Analyst Target Price - Nasdaq
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | See Remarks |
Jun 17 '25 |
Sale |
3.65 |
723 |
2,640 |
183,316 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):